Loading...
Loading...
Size: 5mg
Dual-Action Metabolic Compound
In stock · Ships same day · Free shipping over $150
Technical specifications
Molecular Profile
Dual GIP and GLP-1 receptor agonist (39 amino acids).
Storage Requirements
Lyophilized (powder)
-20°C · stable long-term
Reconstituted / in solution
2-8°C · use within 30 days
Tirzepatide is a 39-amino acid dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist with a C20 fatty diacid modification at Lys20 that enables albumin binding and a pharmacokinetic half-life of approximately 5 days, supporting once-weekly dosing. The peptide backbone is based on the native GIP sequence with engineered GLP-1 receptor cross-reactivity, creating an imbalanced dual agonist with approximately 5-fold greater GIP receptor potency relative to its GLP-1 activity. The SURMOUNT-1 clinical trial published in the New England Journal of Medicine demonstrated mean body weight reductions of 20.9-22.5% over 72 weeks at the 10-15mg weekly doses — the largest weight reductions reported for any single-agent pharmacotherapy at the time of publication. GIP receptor activation on pancreatic beta cells potentiates glucose-dependent insulin secretion, while GLP-1 receptor engagement provides appetite suppression, delayed gastric emptying, and additional incretin effects. Tirzepatide shares its mechanism of action with the FDA-approved products Mounjaro and Zepbound, though this Pepcell product is a research-grade compound manufactured for laboratory investigation, not an FDA-approved pharmaceutical. Active research is investigating tirzepatide's effects on NASH, heart failure with preserved ejection fraction, and obstructive sleep apnea.
Simultaneously activates GIP and GLP-1 receptors through a single peptide molecule with approximately 5-fold greater GIP potency relative to GLP-1 activity. This imbalanced dual agonism distinguishes tirzepatide from both pure GLP-1 agonists and balanced dual agonists, with GIP receptor engagement providing beta-cell insulin potentiation and potential adipose tissue remodeling effects.
The SURMOUNT-1 trial (n=2,539) demonstrated mean body weight reductions of 20.9% (10mg) and 22.5% (15mg) over 72 weeks — the largest reductions observed for any single-agent compound in controlled clinical research at the time. Over one-third of participants in the highest dose group achieved weight reductions exceeding 25% of baseline body weight.
The SURPASS clinical trial program demonstrated HbA1c reductions of 2.0-2.6 percentage points across dose groups in subjects with type 2 diabetes, with up to 97% of participants achieving HbA1c below 7.0%. These glycemic improvements exceeded those observed with comparator GLP-1 agonists in head-to-head studies.
Published research protocols reference weekly subcutaneous administration. Store refrigerated at 2-8°C. Consult applicable literature for specific research applications.
Every batch is independently analyzed by a third-party laboratory for purity and identity before release. A batch-specific Certificate of Analysis (COA) is available for each lot.
Purity
99.2%
Lab
Janoshik Analytical Laboratory
Batch
TIRZEP-2025-001
Test Date
2025-03-23
Orders placed before our daily cutoff ship the same business day. Free shipping on orders over $150, with tracking emailed as soon as your order leaves our facility.
Shipment protection covers your order against loss or damage in transit — if a protected order is lost or arrives damaged, our support team will arrange a replacement or resolution.
For in-vitro research and laboratory use only. This product is not a drug, supplement, food, or cosmetic, and has not been evaluated by the FDA.
Use is restricted to qualified researchers and laboratories operating within all applicable institutional, legal, and ethical guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Tirzepatide is the same active peptide molecule found in FDA-approved Mounjaro (for type 2 diabetes) and Zepbound (for weight management). However, this Pepcell product is a research-grade compound manufactured for laboratory investigation and is not an FDA-approved pharmaceutical. It is not manufactured by Eli Lilly and is not a substitute for prescribed medications.
GIP receptor activation on pancreatic beta cells potentiates glucose-dependent insulin secretion through a signaling pathway complementary to GLP-1. Research also suggests GIP signaling may promote adipose tissue remodeling and improve lipid handling. The dual agonism produces larger metabolic effects than GLP-1 activation alone, as demonstrated in head-to-head clinical trials where tirzepatide outperformed semaglutide.
Reconstitute lyophilized tirzepatide with bacteriostatic water, injecting slowly along the vial wall. The C20 fatty diacid acylation provides excellent solution stability. Do not shake — gentle swirling is acceptable. After reconstitution, store at 2-8°C and use within 30 days.
Each tirzepatide batch undergoes independent HPLC purity analysis and mass spectrometry identity verification at Janoshik Analytical Laboratory. Current batches test at 99%+ purity, with batch-specific Certificates of Analysis available for every lot.
This research-grade tirzepatide is sold exclusively for in-vitro research, laboratory investigation, and educational purposes. It is not an FDA-approved drug product, is not manufactured to pharmaceutical GMP standards, and is not intended for human consumption or self-administration. Individuals seeking tirzepatide for medical use should consult a physician about FDA-approved options.
